ReGelTec

$6Mtotal raised · 2 rounds on record
$4Mlatest round · Venture round · Dec 2019 · 6 yr ago
50+team · employees, estimated range
2018founded

Overview

ReGelTec is developing HYDRAFIL, a next generation treatment for degenerative disc disease.

Funding and backers

Total raised
$6M
2 rounds on record
Latest round
$4M
Venture round · Dec 2019 · 6 yr ago
Team
51-200
employees, estimated range
The money's age
Long since its last round
82 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 12, 2019 Raised a round Venture round $4M · SEC Form D Sep 7, 2018 Raised a round Venture round $2M · SEC Form D 2018 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Dec 2019 $4M — SEC Form D
Venture round Sep 2018 $2M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity ReGelTec, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Mark CollinsExecutive OfficerSEC Form D
William NilandExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
High-Tech Gründerfonds
backs Draupnir Bio
Future Planet Capital
backs Quantum Dice
Bharat Innovates
backs East Ocyon Bio
Band of Angels
backs Atraverse Medical
Springcamp
backs Bell TherapeuticsHealthcare
AIX Ventures
backs Stately Bio
Similar startupsby what they do, their industry and backers
Quantum Dice4 roles
Quantum Dice develops ORBIT probabilistic processors and DISC-certified QRNGs for next-generation computing and cryptographic security.
Bell TherapeuticsHealthcareFounded 2023
Innovating Digital Healthcare for a Better Tomorrow. Founded in 2023, BELL Therapeutics applies original biotechnology and advanced…
Alveron PharmaSeed $5.4M · 23 mo ago · 11-50 employees
Alveron Pharma is developing a unique coagulationplatform technology with the world.
Draupnir BioSeed $13M · 2 yr ago
Draupnir Bio is developing new innovative therapies for patients.
Stately BioSeed $12M · 18 mo ago · 1-10 employees
Stately Bio is developing the next generation of life-saving regenerative medicines with the world.
Atraverse MedicalVenture round $29M · 16 mo ago · Founded 2022 · 51-200 employees
Developing the next generation of left-heart access technologies.

Financials

Total raised
$6M
Latest round
Venture - Series Unknown
Funding rounds
2
Funding rounds
Round Announced Amount
Venture - Series Unknown 2019 $4M Details
Venture - Series Unknown 2018 $2M Details

People

Mark Collins
Executive Officer
SEC Form D
William Niland
Executive Officer, Director
SEC Form D
Anthony Lowman
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Baltimore United States
HQ
50-200 est. staff